Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Net Margin (2016 - 2025)

Historic Net Margin for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to 162.11%.

  • Marker Therapeutics' Net Margin fell 422600.0% to 162.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 846.98%, marking a year-over-year increase of 9587000.0%. This contributed to the annual value of 5365.68% for FY2024, which is 55411200.0% down from last year.
  • Marker Therapeutics' Net Margin amounted to 162.11% in Q3 2025, which was down 422600.0% from 479.92% recorded in Q2 2025.
  • Marker Therapeutics' 5-year Net Margin high stood at 867.33% for Q2 2023, and its period low was 1273.6% during Q1 2025.
  • Moreover, its 4-year median value for Net Margin was 119.59% (2022), whereas its average is 225.97%.
  • Per our database at Business Quant, Marker Therapeutics' Net Margin skyrocketed by 13747800bps in 2023 and then crashed by -10812600bps in 2025.
  • Marker Therapeutics' Net Margin (Quarter) stood at 107.1% in 2022, then skyrocketed by 94bps to 5.96% in 2023, then surged by 1636bps to 91.5% in 2024, then plummeted by -277bps to 162.11% in 2025.
  • Its Net Margin stands at 162.11% for Q3 2025, versus 479.92% for Q2 2025 and 1273.6% for Q1 2025.